Skip to main content

Boehringer Ingelheim acquires T3 Pharma

| News

Boehringer Ingelheim acquires T3 Pharma


Boehringer Ingelheim has acquired T3 Pharma, which is based in the Switzerland Innovation Park Basel Area, for an amount of up to 450 million Swiss francs. The specialist in bacterial cancer therapy will continue to operate in the Basel Area.

Simon Ittig, founder and CEO of T3 Pharma (image: T3 Pharma)

T3 Pharmaceuticals AG is being acquired by Boehringer Ingelheim for up to 450 million Swiss francs. With T3 Pharma, the German pharmaceutical group, which has a branch in Basel, is acquiring a clinical-stage biotech company based on the main campus of the Switzerland Innovation Park Basel Area in Allschwil in the canton of Basel-Landschaft. During its launch seven years ago, it was supported by the startup accelerator and incubator BaseLaunch. According to a statement, T3’s activities will remain in the Basel Area.

T3 Pharma, a spin-off of the University of Basel, has developed a therapeutic platform that uses live bacteria to deliver immunomodulatory proteins into cancer cells and tumor microenvironments. Boehringer Ingelheim describes this bacterial cancer therapy as groundbreaking. “This will bring us closer to achieving our vision of driving a paradigm shift in cancer care treatments,” said Michel Pairet, Member of the Board of Managing Directors at Boehringer Ingelheim with responsibility for the Innovation Unit, in the statement.

Second acquisition of Boehringer in Basel

The T3 Pharma team is excited to continue and accelerate “the successful development of our bacterial delivery platform as part of Boehringer Ingelheim,” according to CEO Simon Ittig. He said: “Being integrated with our partners at Boehringer will enable us to realize the full potential of our platform to fight solid cancers.”

In 2020, Boehringer acquired NBE-Therapeutics, a Basel-based life sciences company. The purchase price at the time was €1.18 billion.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.